Cargando…
Clinical validation of an artificial intelligence-based diabetic retinopathy screening tool for a national health system
OBJECTIVE: To evaluate the accuracy and validity of an automated diabetic retinopathy (DR) screening tool (DART, TeleDx, Santiago, Chile) that uses artificial intelligence to analyze ocular fundus photographs for potential implementation in the national Chilean DR screening programme. METHOD: This w...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727616/ https://www.ncbi.nlm.nih.gov/pubmed/33432168 http://dx.doi.org/10.1038/s41433-020-01366-0 |
_version_ | 1784626561525219328 |
---|---|
author | Arenas-Cavalli, José Tomás Abarca, Ignacio Rojas-Contreras, Maximiliano Bernuy, Fernando Donoso, Rodrigo |
author_facet | Arenas-Cavalli, José Tomás Abarca, Ignacio Rojas-Contreras, Maximiliano Bernuy, Fernando Donoso, Rodrigo |
author_sort | Arenas-Cavalli, José Tomás |
collection | PubMed |
description | OBJECTIVE: To evaluate the accuracy and validity of an automated diabetic retinopathy (DR) screening tool (DART, TeleDx, Santiago, Chile) that uses artificial intelligence to analyze ocular fundus photographs for potential implementation in the national Chilean DR screening programme. METHOD: This was an observational study of 1123 diabetic eye exams using a validation protocol designed by the commission of the Chilean Ministry of Health personnel and retina specialists. RESULTS: Receiver operating characteristic (ROC) analysis indicated a sensitivity of 94.6% (95% CI: 90.9–96.9%), specificity of 74.3% (95% CI: 73.3–75%), and negative predictive value of 98.1% (95% CI: 96.8–98.9%) for the automated tool at the optimal operating point for DR screening. The area under the ROC curve was 0.915. CONCLUSIONS: The results of this study suggest that DART is a valid tool that could be implemented in a heterogeneous health network such as the Chilean system. |
format | Online Article Text |
id | pubmed-8727616 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-87276162022-01-18 Clinical validation of an artificial intelligence-based diabetic retinopathy screening tool for a national health system Arenas-Cavalli, José Tomás Abarca, Ignacio Rojas-Contreras, Maximiliano Bernuy, Fernando Donoso, Rodrigo Eye (Lond) Article OBJECTIVE: To evaluate the accuracy and validity of an automated diabetic retinopathy (DR) screening tool (DART, TeleDx, Santiago, Chile) that uses artificial intelligence to analyze ocular fundus photographs for potential implementation in the national Chilean DR screening programme. METHOD: This was an observational study of 1123 diabetic eye exams using a validation protocol designed by the commission of the Chilean Ministry of Health personnel and retina specialists. RESULTS: Receiver operating characteristic (ROC) analysis indicated a sensitivity of 94.6% (95% CI: 90.9–96.9%), specificity of 74.3% (95% CI: 73.3–75%), and negative predictive value of 98.1% (95% CI: 96.8–98.9%) for the automated tool at the optimal operating point for DR screening. The area under the ROC curve was 0.915. CONCLUSIONS: The results of this study suggest that DART is a valid tool that could be implemented in a heterogeneous health network such as the Chilean system. Nature Publishing Group UK 2021-01-11 2022-01 /pmc/articles/PMC8727616/ /pubmed/33432168 http://dx.doi.org/10.1038/s41433-020-01366-0 Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Arenas-Cavalli, José Tomás Abarca, Ignacio Rojas-Contreras, Maximiliano Bernuy, Fernando Donoso, Rodrigo Clinical validation of an artificial intelligence-based diabetic retinopathy screening tool for a national health system |
title | Clinical validation of an artificial intelligence-based diabetic retinopathy screening tool for a national health system |
title_full | Clinical validation of an artificial intelligence-based diabetic retinopathy screening tool for a national health system |
title_fullStr | Clinical validation of an artificial intelligence-based diabetic retinopathy screening tool for a national health system |
title_full_unstemmed | Clinical validation of an artificial intelligence-based diabetic retinopathy screening tool for a national health system |
title_short | Clinical validation of an artificial intelligence-based diabetic retinopathy screening tool for a national health system |
title_sort | clinical validation of an artificial intelligence-based diabetic retinopathy screening tool for a national health system |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727616/ https://www.ncbi.nlm.nih.gov/pubmed/33432168 http://dx.doi.org/10.1038/s41433-020-01366-0 |
work_keys_str_mv | AT arenascavallijosetomas clinicalvalidationofanartificialintelligencebaseddiabeticretinopathyscreeningtoolforanationalhealthsystem AT abarcaignacio clinicalvalidationofanartificialintelligencebaseddiabeticretinopathyscreeningtoolforanationalhealthsystem AT rojascontrerasmaximiliano clinicalvalidationofanartificialintelligencebaseddiabeticretinopathyscreeningtoolforanationalhealthsystem AT bernuyfernando clinicalvalidationofanartificialintelligencebaseddiabeticretinopathyscreeningtoolforanationalhealthsystem AT donosorodrigo clinicalvalidationofanartificialintelligencebaseddiabeticretinopathyscreeningtoolforanationalhealthsystem |